Loading...
XLON
CTEC
Market cap6.58bUSD
Apr 04, Last price  
250.40GBP
1D
-3.02%
1Q
14.23%
Jan 2017
7.05%
IPO
9.34%
Name

ConvaTec Group PLC

Chart & Performance

D1W1MN
P/E
5,050.18
P/S
307.15
EPS
0.06
Div Yield, %
1.55%
Shrs. gr., 5y
0.95%
Rev. gr., 5y
3.18%
Revenues
2.14b
+3.37%
1,700,700,0001,733,900,0001,650,400,0001,688,300,0001,764,600,0001,832,100,0001,827,200,0001,894,300,0002,038,300,0002,072,500,0002,142,400,000
Net income
130m
+107.15%
-173,700,000-286,500,000-93,400,000-202,800,000158,400,000221,600,0009,800,000112,500,000117,600,00062,900,000130,300,000
CFO
367m
+30.42%
229,100,000147,300,000100,300,00074,900,000306,600,000352,000,000401,800,000399,500,000305,900,000281,700,000367,400,000
Dividend
Aug 22, 20241.0763 GBP/sh
Earnings
May 16, 2025

Profile

ConvaTec Group Plc develops, manufactures, and markets medical products and technologies worldwide. It offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, immobility, and venous disease, as well as from traumatic injury, burns, invasive surgery, and other causes. The company also provides devices, accessories, and services for people with a stoma resulting from colorectal cancer, inflammatory bowel disease, bladder cancer, obesity, and other causes. In addition, it offers continence and critical care products, including intermittent urinary catheters; and products for people with urinary continence issues related to spinal cord injuries, multiple sclerosis, spina bifida, and other urological disorders, as well as devices and products used in intensive care units and hospital settings. Further, the company provides advanced systems for managing acute fecal incontinence, as well as for monitoring urine production output and intra-abdominal pressure; and various disposable medical devices, such as wound drainage systems, urine collection bags and catheters, airway management and oxygen/aerosol therapy devices, suction handles and tubes, gastroenterology tubes, and securement devices. Additionally, it offers disposable infusion sets to manufacturers of insulin pumps for diabetes, as well as similar pumps that are used in continuous infusion treatments for other conditions; and various products to hospital and home healthcare markets. The company sells its products to pharmacies, hospitals, and other acute and post-acute healthcare service providers directly or through distributors and wholesalers. It serves a range of customers, including healthcare providers, patients, and manufacturers. The company was founded in 1978 and is headquartered in Reading, the United Kingdom.
IPO date
Oct 26, 2016
Employees
10,000
Domiciled in
GB
Incorporated in
GB

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
2,142,400
3.37%
2,072,500
1.68%
Cost of revenue
1,859,500
1,817,800
Unusual Expense (Income)
NOPBT
282,900
254,700
NOPBT Margin
13.20%
12.29%
Operating Taxes
37,100
19,000
Tax Rate
13.11%
7.46%
NOPAT
245,800
235,700
Net income
130,300
107.15%
62,900
-46.51%
Dividends
(110,700)
(88,100)
Dividend yield
2.21%
1.86%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
20,700
20,300
Long-term debt
1,377,200
1,300,500
Deferred revenue
1,129,000
Other long-term liabilities
192,900
(1,212,200)
Net debt
1,276,700
1,144,100
Cash flow
Cash from operating activities
367,400
281,700
CAPEX
(129,200)
(144,200)
Cash from investing activities
(285,700)
(348,300)
Cash from financing activities
(124,000)
(237,100)
FCF
95,000
216,200
Balance
Cash
98,300
145,800
Long term investments
22,900
30,900
Excess cash
14,080
73,075
Stockholders' equity
(637,200)
1,445,500
Invested Capital
3,835,200
2,863,425
ROIC
7.34%
10.67%
ROCE
8.85%
8.43%
EV
Common stock shares outstanding
2,052,589
2,040,247
Price
2.44
4.99%
2.33
20.42%
Market cap
5,012,423
5.62%
4,745,616
21.25%
EV
6,289,123
5,889,716
EBITDA
497,700
450,800
EV/EBITDA
12.64
13.07
Interest
73,300
64,700
Interest/NOPBT
25.91%
25.40%